Blade Therapeutics expands anti-fibrotic pipeline with acquisition of ATXCo and its autotaxin inhibitor

Image: Blade Therapeutics has expanded its anti-fibrotic pipeline with acquisition of ATXCo. Photo: courtesy of rawpixel from Pixabay.